Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8776 to 8790 of 8945 results

  1. Ovarian cancer patients to have NICE-approved drug combination option on Cancer Drugs Fund

    A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer will now be available on the Cancer Drugs Fund (CDF), following its approval by NICE in draft guidance published today.

  2. Over 700 people a year could benefit from a new lung cancer drug

    An innovative and potentially life-extending drug for treating people with a specific gene mutation of advanced non-small-cell lung cancer (NSCLC) has been recommended by NICE and will be available to patients from today (Thursday, 14 April).

  3. Patients with rare blood disorders to receive new treatment option, says NICE

    In final guidance published today (20 May 2021), NICE has recommended ravulizumab (Ultomiris, Alexion Pharmaceuticals) as a treatment for paroxysmal nocturnal haemoglobinuria (PNH). Draft guidance published 19 May 2021 also recommends the treatment for atypical haemolytic uraemic syndrome (aHUS).

  4. New treatment option for adults with obesity and non-diabetic hyperglycaemia

    All eligibility criteria must be met for Liraglutide to be offered.

  5. Women should be offered induced labour earlier than previously advised

    Induced labour should be offered earlier than previously advised to make birth safer for women and their babies, according to draft guidelines published by NICE today (25 May 2021). The updated recommendations strengthen previous advice in the light of new evidence on induction timings.

  6. Around 100,000 fewer colonoscopies expected to take place each year

    Tens of thousands of people a year could be spared the need for a colonoscopy following new guidance from NICE.

  7. New treatment option recommended for people with type 2 diabetes

    Around 180,000 people with difficult to manage type 2 diabetes could benefit from tirzepatide as new treatment option for type 2 diabetes.

  8. Digital services to enable easier access to weight management support

    Four digital programmes can be used to help the NHS deliver specialist weight management services to support the use of medication in England

  9. Speaking with one language: How using a common data model might speed up decision making

    The European Health Data and Evidence Network (EHDEN) project could support faster patient access to innovative medicines in areas of unmet need.

  10. NICE announces proposals to transform its HealthTech programme to drive more technology into the NHS

    Consultation launches on the biggest shake-up of NICE's HealthTech programme to date.

  11. NICE has made six times more lung cancer treatment recomendations over the past ten years than in the previous decade

    We have also recommended osimertinib for routine use on the NHS today.

  12. NICE recommends new treatment to prevent and reduce hearing loss in people being treated for cancer

    For the first time, NICE has recommended an innovative new treatment to help stop babies, children and young people who are undergoing cancer treatment from losing their hearing.

  13. Over 1000 people with advanced breast cancer set to benefit from new once-a-day tablet

    We’ve issued final draft guidance recommending a new once-a-day tablet that is set to benefit around 1,100 people with a type of advanced breast cancer.

  14. Public consultation launched on changes to NICE's Highly Specialised Technologies routing criteria

    NICE is proposing changes to its routing criteria for Highly Specialised Technologies (HST) to ensure more consistent, predictable and transparent decisions.

  15. New price deal paves way for NICE approval of treatment for rare genetic condition

    A new treatment for Duchenne muscular dystrophy (DMD) is set to be available to around 1,700 people in England following positive final draft guidance from NICE published today.